Burke W J, Ranno A E, Roccaforte W H, Wengel S P, Bayer B L, Willcockson N K
Creighton-Nebraska Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198-5575.
J Am Geriatr Soc. 1993 Apr;41(4):367-70. doi: 10.1111/j.1532-5415.1993.tb06942.x.
To examine the short-term cognitive and behavioral effects of L-deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2-month period.
A 15-month randomized, double-blind, placebo-controlled trial using a parallel-group design. This report deals with the first 2 months of the trial.
39 subjects with mild DAT (CDR 1) selected using NINCDS-ADRDA criteria.
A battery of neuropsychological tests and clinical rating scales.
The placebo and L-deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L-deprenyl effect on any clinical or neuropsychological measures after 2 months.
L-deprenyl did not have a measurable impact on behavior or cognitive function over a 2-month period in this group of subjects with mild DAT.
研究L-司来吉兰对轻度阿尔茨海默型痴呆（DAT）患者在2个月期间的短期认知和行为影响。
采用平行组设计的15个月随机、双盲、安慰剂对照试验。本报告涉及试验的前2个月。
根据NINCDS-ADRDA标准选取的39例轻度DAT（临床痴呆评定量表[CDR]评分为1）患者。
一系列神经心理学测试和临床评定量表。
在临床和神经心理学测试中，安慰剂组和L-司来吉兰组受试者在基线时相似。2个月后，没有证据表明L-司来吉兰对任何临床或神经心理学指标有影响。
在这组轻度DAT患者中，L-司来吉兰在2个月期间对行为或认知功能没有可测量的影响。
